Osaka-founded Kringle has increased its round to $15.5m thanks to investors including OUVC in order to fund development of its rare disease treatments.

Kringle Pharma, a Japan-based cell therapy developer spun out of Osaka University, has closed a ¥1.69bn ($15.5m) funding round after raising $6.8m from investors including Osaka University Venture Capital, the institution’s investment arm.
MSF Capital Partners, the corporate venturing arm of clinical services provider Miraca, and property developer Chishima Real Estate also took part in the round, as did financial services firms Nanto Bank, Ogaki Kyoritsu Bank and Resona Bank, the latter two supplying funding through OKB Capital and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in